Aduro and Janssen Initiate Prostate Cancer Clinical Trial

Aduro and Janssen Initiate Prostate Cancer Clinical Trial
Private immuno-oncology company Aduro Biotech Inc. recently announced that they will partner with Janssen Biotech Inc. on a series of toxicology studies to support an Investigational New Drug Application for ADU-741 in prostate cancer treatment. Prostate cancer is the second most common cancer among men in the United States. It is a curable cancer that usually features slow growth

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *